Effect of nadcin on energy supply system and apoptosis in ischemia-reperfusion injury to the myocardium

Bulletin of Experimental Biology and Medicine

Volumn 146, Issue 3, 2008, Pages 321-324

  Sukoyan, G V ^a   Kavadze, I K ^a  

^a NV Karsanov Republican Res Ctr Med Biophysics/Implementation of New Biomed Technol   (Georgia)

Author keywords

Apoptosis; Energy supply system; Ischemia; Nadcin; Reperfusion

Indexed keywords

ADENINE NUCLEOTIDE; CARDIOVASCULAR AGENT; CREATINE PHOSPHATE; INOSINE; NADCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLACEBO; PYRIDINE NUCLEOTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOG; DRUG MECHANISM; ENERGY RESOURCE; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; MALE; MITOCHONDRION; NONHUMAN; OXIDATION REDUCTION POTENTIAL; PROTEIN ANALYSIS; PROTEIN CONTENT;

ADENINE NUCLEOTIDES; ANIMALS; APOPTOSIS; DOGS; DRUG COMBINATIONS; ENERGY METABOLISM; FEMALE; INOSINE; MALE; MYOCARDIAL REPERFUSION INJURY; NAD; POLY(ADP-RIBOSE) POLYMERASES;

CANIS FAMILIARIS;

EID: 58249128000     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10517-008-0268-2     Document Type: Article

References (15)

1. N. V. Karsanov, G. V. Sukoyan, E. A. Chikobava, et al., Byull. Eksp. Biol. Med., 134, No. 9, 338-345 (2002).
2. G. V. Sukoyan, E. A. Chikobava, and D. R. Tatulashvili, Eksper. Klin. Farmakol., No. 4, 34-38 (2003).
3. G. V. Sukoyan, N. A. Andriadze, E. I. Guchua, and N. V. Karsanov, Byull. Eksp. Biol. Med., 139, No. 1, 53-56 (2005).
4. M. Akao, Y. Teshima, and E. Marban, J. Am. Coll. Cardiol., 40, No. 4, 803-810 (2002).
5. P. M. Barger and D. P. Kelly, Trends Cardiovasc. Med., 10, No. 6, 238-245 (2000).
6. R. Bortell, J. Moss, R. C. McKenna, et al., J. Immunol., 167, No. 4, 2049-2059 (2001).
7. M. V. Cohen, X. M. Yang, T. Neumann, et al., Circulation, 102, No. 5, 579-583 (2000).
8. G. Hasko, M. V. Sitkovsky, and C. Szabo, TRENDS Pharmacol. Sci., 25, No. 3, 152-157 (2004).
9. B. S. Khakh and G. Henderson, Mol. Pharmacol., 54, No. 2, 372-378 (1998).
10. J. Marin-Garcia and M. J. Goldenthal, J. Card. Fail., 10, No. 1, 55-66 (2004).
11. N. A. Riobo, E. Clement, M. Melani, et al., Biochem. J., 359, Pt. 1, 139-145 (2001).
12. I. U. Schraufstatter, D. B. Hinshaw, P. A. Hyslop, et al., J. Clin. Invest., 77, No. 4, 1312-1320 (1986).
13. R. Schulz, M. V. Cohen, M. Behrends, et al., Cardiovasc. Res., 52, No. 2, 181-198 (2001).
14. M. G. Sutton and N. Sharpe, Circulation, 101, No. 25, 2981-2988 (2000).
15. L. Virag and C. Szabo, FASEB J., 15, No. 1, 99-107 (2001).